Caris Life Sciences, Inc.
CAI
$24.03
-$0.79-3.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 263.71M | 216.17M | 292.89M | 216.83M | 181.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 263.71M | 216.17M | 292.89M | 216.83M | 181.40M |
| Cost of Revenue | 84.12M | 74.83M | 70.10M | 69.33M | 67.71M |
| Gross Profit | 179.60M | 141.35M | 222.78M | 147.51M | 113.69M |
| SG&A Expenses | 120.31M | 104.75M | 104.55M | 93.24M | 106.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 236.79M | 210.89M | 204.48M | 184.19M | 199.39M |
| Operating Income | 26.93M | 5.28M | 88.41M | 32.64M | -17.99M |
| Income Before Tax | -614.00K | -644.00K | 81.96M | 24.33M | -71.79M |
| Income Tax Expenses | 23.00K | -134.00K | -- | -- | -- |
| Earnings from Continuing Operations | -637.00K | -510.00K | 81.96M | 24.33M | -71.79M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -637.00K | -510.00K | 81.96M | 24.33M | -71.79M |
| EBIT | 26.93M | 5.28M | 88.41M | 32.64M | -17.99M |
| EBITDA | 33.46M | 10.35M | 92.70M | 37.51M | -11.58M |
| EPS Basic | 0.00 | 0.00 | 0.29 | 0.09 | -7.97 |
| Normalized Basic EPS | 0.05 | 0.00 | 0.19 | 0.05 | -0.52 |
| EPS Diluted | 0.00 | 0.00 | 0.28 | 0.08 | -7.97 |
| Normalized Diluted EPS | 0.05 | 0.00 | 0.18 | 0.05 | -0.52 |
| Average Basic Shares Outstanding | 282.89M | 282.56M | 282.22M | 282.10M | 64.92M |
| Average Diluted Shares Outstanding | 282.89M | 282.56M | 296.09M | 297.21M | 64.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |